tiprankstipranks
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
US Market
APLS
Apellis Pharmaceuticals
RESEARCH TOOLSreports

Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

Compare
999 Followers
See the Price Targets and Ratings of:

APLS Analyst Ratings

Moderate Buy
16Ratings
Moderate Buy
11 Buy
5 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Apellis
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

APLS Stock 12 Month Forecast

Average Price Target

$31.27
▲(77.27% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $31.27 with a high forecast of $48.00 and a low forecast of $18.00. The average price target represents a 77.27% change from the last price of $17.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","49":"$49","24.25":"$24.3","32.5":"$32.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,24.25,32.5,40.75,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.7,22.8,24.9,27,29.1,31.2,33.3,35.4,37.5,39.6,41.7,43.8,45.900000000000006,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.7,21.513076923076923,22.326153846153847,23.139230769230767,23.95230769230769,24.765384615384615,25.57846153846154,26.39153846153846,27.204615384615384,28.017692307692307,28.83076923076923,29.643846153846155,30.456923076923076,{"y":31.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.7,20.49230769230769,20.284615384615385,20.076923076923077,19.869230769230768,19.661538461538463,19.453846153846154,19.246153846153845,19.038461538461537,18.83076923076923,18.623076923076923,18.415384615384614,18.20769230769231,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.87,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.47,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.83,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$48.00Average Price Target$31.27Lowest Price Target$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on APLS
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$17.72→$20
Hold
13.38%
Upside
Reiterated
03/26/26
Mizuho Securities Remains a Hold on Apellis Pharmaceuticals (APLS)
Cantor Fitzgerald Analyst forecast on APLS
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$35→$31
Buy
75.74%
Upside
Reiterated
03/17/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)
Roth MKM Analyst forecast on APLS
Adam Walsh
Roth MKM
Roth MKM
$31
Buy
75.74%
Upside
Initiated
03/13/26
Analysts' Top Healthcare Picks: Apellis Pharmaceuticals (APLS), Argenx Se (ARGX)
J.P. Morgan Analyst forecast on APLS
Anupam Rama
J.P. Morgan
J.P. Morgan
$36→$37
Buy
109.75%
Upside
Reiterated
03/05/26
Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS)
William Blair Analyst forecast on APLS
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (NASDAQ: ACLX) and Apellis Pharmaceuticals (NASDAQ: APLS)
H.C. Wainwright Analyst forecast on APLS
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$45→$48
Buy
172.11%
Upside
Reiterated
02/25/26
Analysts Are Bullish on Top Healthcare Stocks: Palisade Bio (PALI), Apellis Pharmaceuticals (APLS)
Wedbush Analyst forecast on APLS
Laura Chico
Wedbush
Wedbush
$20→$18
Hold
2.04%
Upside
Reiterated
02/25/26
Wedbush Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
Barclays Analyst forecast on APLS
Eliana Merle
Barclays
Barclays
$24
Hold
36.05%
Upside
Reiterated
02/25/26
Barclays Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)
Citi Analyst forecast on APLS
Yigal Nochomovitz
Citi
Citi
$45→$44
Buy
149.43%
Upside
Reiterated
02/25/26
Citi Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)
Morgan Stanley Analyst forecast on APLS
Judah Frommer
Morgan Stanley
Morgan Stanley
$25
Hold
41.72%
Upside
Reiterated
02/25/26
Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating
Needham Analyst forecast on APLS
Joseph Stringer
Needham
Needham
$28
Buy
58.73%
Upside
Reiterated
02/24/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on APLS
Phil Nadeau
TD Cowen
TD Cowen
$45→$40
Buy
126.76%
Upside
Reiterated
02/24/26
Apellis Pharmaceuticals: Solid Syfovre Franchise and Rapid Empaveli Uptake Underpin Buy Rating and Long-Term Upside
Bank of America Securities Analyst forecast on APLS
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$28
Buy
58.73%
Upside
Reiterated
02/24/26
Apellis Pharmaceuticals: Buy Rating Supported by Blockbuster Empaveli Potential, Sustainable Syfovre Growth, and Expanding Kidney Franchise
RBC Capital Analyst forecast on APLS
Lisa Walter
RBC Capital
RBC Capital
$22→$21
Hold
19.05%
Upside
Reiterated
02/24/26
RBC Capital Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Wells Fargo Analyst forecast on APLS
Derek Archila
Wells Fargo
Wells Fargo
$29→$26
Buy
47.39%
Upside
Reiterated
01/20/26
Wells Fargo Remains a Buy on Apellis Pharmaceuticals (APLS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on APLS
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$17.72→$20
Hold
13.38%
Upside
Reiterated
03/26/26
Mizuho Securities Remains a Hold on Apellis Pharmaceuticals (APLS)
Cantor Fitzgerald Analyst forecast on APLS
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$35→$31
Buy
75.74%
Upside
Reiterated
03/17/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)
Roth MKM Analyst forecast on APLS
Adam Walsh
Roth MKM
Roth MKM
$31
Buy
75.74%
Upside
Initiated
03/13/26
Analysts' Top Healthcare Picks: Apellis Pharmaceuticals (APLS), Argenx Se (ARGX)
J.P. Morgan Analyst forecast on APLS
Anupam Rama
J.P. Morgan
J.P. Morgan
$36→$37
Buy
109.75%
Upside
Reiterated
03/05/26
Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS)
William Blair Analyst forecast on APLS
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (NASDAQ: ACLX) and Apellis Pharmaceuticals (NASDAQ: APLS)
H.C. Wainwright Analyst forecast on APLS
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$45→$48
Buy
172.11%
Upside
Reiterated
02/25/26
Analysts Are Bullish on Top Healthcare Stocks: Palisade Bio (PALI), Apellis Pharmaceuticals (APLS)
Wedbush Analyst forecast on APLS
Laura Chico
Wedbush
Wedbush
$20→$18
Hold
2.04%
Upside
Reiterated
02/25/26
Wedbush Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
Barclays Analyst forecast on APLS
Eliana Merle
Barclays
Barclays
$24
Hold
36.05%
Upside
Reiterated
02/25/26
Barclays Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)
Citi Analyst forecast on APLS
Yigal Nochomovitz
Citi
Citi
$45→$44
Buy
149.43%
Upside
Reiterated
02/25/26
Citi Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)
Morgan Stanley Analyst forecast on APLS
Judah Frommer
Morgan Stanley
Morgan Stanley
$25
Hold
41.72%
Upside
Reiterated
02/25/26
Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating
Needham Analyst forecast on APLS
Joseph Stringer
Needham
Needham
$28
Buy
58.73%
Upside
Reiterated
02/24/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on APLS
Phil Nadeau
TD Cowen
TD Cowen
$45→$40
Buy
126.76%
Upside
Reiterated
02/24/26
Apellis Pharmaceuticals: Solid Syfovre Franchise and Rapid Empaveli Uptake Underpin Buy Rating and Long-Term Upside
Bank of America Securities Analyst forecast on APLS
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$28
Buy
58.73%
Upside
Reiterated
02/24/26
Apellis Pharmaceuticals: Buy Rating Supported by Blockbuster Empaveli Potential, Sustainable Syfovre Growth, and Expanding Kidney Franchise
RBC Capital Analyst forecast on APLS
Lisa Walter
RBC Capital
RBC Capital
$22→$21
Hold
19.05%
Upside
Reiterated
02/24/26
RBC Capital Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Wells Fargo Analyst forecast on APLS
Derek Archila
Wells Fargo
Wells Fargo
$29→$26
Buy
47.39%
Upside
Reiterated
01/20/26
Wells Fargo Remains a Buy on Apellis Pharmaceuticals (APLS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Apellis Pharmaceuticals

3 Months
xxx
Success Rate
22/37 ratings generated profit
59%
Average Return
+1.30%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 59.46% of your transactions generating a profit, with an average return of +1.30% per trade.
1 Year
Steven SeedhouseCantor Fitzgerald
Success Rate
11/31 ratings generated profit
35%
Average Return
-5.05%
Copying Steven Seedhouse's trades and holding each position for 1 Year would result in 35.48% of your transactions generating a profit, with an average return of -5.05% per trade.
2 Years
xxx
Success Rate
14/31 ratings generated profit
45%
Average Return
-3.13%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 45.16% of your transactions generating a profit, with an average return of -3.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

APLS Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
10
11
10
11
12
Buy
5
6
11
13
12
Hold
10
11
11
16
17
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
28
32
40
41
In the current month, APLS has received 24 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. APLS average Analyst price target in the past 3 months is 31.27.
Each month's total comprises the sum of three months' worth of ratings.

APLS Financial Forecast

APLS Earnings Forecast

Next quarter’s earnings estimate for APLS is -$0.35 with a range of -$0.62 to -$0.17. The previous quarter’s EPS was -$0.47. APLS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year APLS has Performed in-line its overall industry.
Next quarter’s earnings estimate for APLS is -$0.35 with a range of -$0.62 to -$0.17. The previous quarter’s EPS was -$0.47. APLS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year APLS has Performed in-line its overall industry.

APLS Sales Forecast

Next quarter’s sales forecast for APLS is $203.25M with a range of $170.00M to $228.00M. The previous quarter’s sales results were $199.91M. APLS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year APLS has Performed in-line its overall industry.
Next quarter’s sales forecast for APLS is $203.25M with a range of $170.00M to $228.00M. The previous quarter’s sales results were $199.91M. APLS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year APLS has Performed in-line its overall industry.

APLS Stock Forecast FAQ

What is APLS’s average 12-month price target, according to analysts?
Based on analyst ratings, Apellis Pharmaceuticals Inc’s 12-month average price target is 31.27.
    What is APLS’s upside potential, based on the analysts’ average price target?
    Apellis Pharmaceuticals Inc has 77.27% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is APLS a Buy, Sell or Hold?
          Apellis Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 11 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Apellis Pharmaceuticals Inc’s price target?
            The average price target for Apellis Pharmaceuticals Inc is 31.27. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $48.00 ,the lowest forecast is $18.00. The average price target represents 77.27% Increase from the current price of $17.64.
              What do analysts say about Apellis Pharmaceuticals Inc?
              Apellis Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of APLS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.